Phase 1 Open Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines
Latest Information Update: 22 Nov 2022
At a glance
- Drugs INO 4800 (Primary) ; INO 9112 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 12 Nov 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Aug 2022 Trial design changed from randomized to non-randomized.
- 18 Aug 2022 Planned End Date changed from 1 Aug 2023 to 1 Mar 2024.